Exact Mass: 427.2470938000001
Exact Mass Matches: 427.2470938000001
Found 14 metabolites which its exact mass value is equals to given mass value 427.2470938000001,
within given mass tolerance error 1.6E-6 dalton. Try search metabolite list with more accurate mass tolerance error
3.2E-7 dalton.
Ranolazine
C24H33N3O4 (427.2470938000001)
Ranolazine is only found in individuals that have used or taken this drug. It is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia. C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
RANOLAZINE
C24H33N3O4 (427.2470938000001)
C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Ivaltinostat
C24H33N3O4 (427.2470938000001)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
4-[(4-Cyclohexyl-1-piperazinyl)-oxomethyl]-2-ethyl-6,7-dimethoxy-1-isoquinolinone
C24H33N3O4 (427.2470938000001)
(2R,3R,3aS,9bS)-N-(cyclohexylmethyl)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C24H33N3O4 (427.2470938000001)
(2S,3S,3aR,9bR)-N-(cyclohexylmethyl)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C24H33N3O4 (427.2470938000001)
1-[(1S)-2-acetyl-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-1-butanone
C24H33N3O4 (427.2470938000001)
1-[(1R)-2-acetyl-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-1-butanone
C24H33N3O4 (427.2470938000001)
(1R,9S,10S,11S)-12-acetyl-N-(cyclohexylmethyl)-10-(hydroxymethyl)-6-oxo-5-[(Z)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C24H33N3O4 (427.2470938000001)
(1S,9R,10R,11R)-12-acetyl-N-(cyclohexylmethyl)-10-(hydroxymethyl)-6-oxo-5-[(Z)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C24H33N3O4 (427.2470938000001)
(3s,6s)-3-({5-[(2s)-2,3-dihydroxy-3-methylbutyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methyl)-6-methyl-3,6-dihydropyrazine-2,5-diol
C24H33N3O4 (427.2470938000001)
3-{[5-(2,3-dihydroxy-3-methylbutyl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
C24H33N3O4 (427.2470938000001)
